# Stéphane Dalle

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/stephane-dalle/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,936 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 74 |
| i10-index | 288 |
| Last Known Institution | Université Claude Bernard Lyon 1 |
| OpenAlex ID | https://openalex.org/A5073133195 |
| ORCID iD | https://orcid.org/0000-0002-3423-4548 |
| Works | 836 |

## Researcher papers

- [Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma/)
- [Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study](https://scholariq.org/papers/epacadostat-plus-pembrolizumab-versus-placebo-plus-pembrolizumab-in-patients/)
- [Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial](https://scholariq.org/papers/mogamulizumab-versus-vorinostat-in-previously-treated-cutaneous-t-cell-lymphoma/)
- [Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-nivolumab-versus-ipilimumab-in-resected-stage-iiib-c-and-stage-iv/)
- [Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients](https://scholariq.org/papers/immune-checkpoint-inhibitors-associated-with-interstitial-lung-disease-in-cancer/)
- [Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325/)
- [Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial](https://scholariq.org/papers/cemiplimab-in-locally-advanced-basal-cell-carcinoma-after-hedgehog-inhibitor/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Cutaneous lymphoproliferative disorders research](https://scholariq.org/topics/cutaneous-lymphoproliferative-disorders-research/)

## Researcher university

- [Lyon 1 Université](https://scholariq.org/institutions/lyon-1-universite/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.